Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma
Diagnosis of follicular lymphoma (FL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia (CLL) (meeting International Workshop on Chronic Lymphocytic Leukemia [IWCLL] Criteria ), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM), or non-germinal center B-cell lymphoma (GCB) diffuse large B-cell lymphoma (DLBCL) as documented by medical records on WHO criteria
Chronic lymphocytic leukemia /small lymphocytic lymphoma (CLL/SLL), marginal zone B-cell lymphoma, lymphoplasmacytic lymphoma or follicular lymphoma that have progressed after at least two different prior therapies; patients with bulky disease (nodal mass greater than  cm) should be considered for debulking chemotherapy before transplant; these patients must be presented at primary care center (PCC) prior to enrollment, given potential competing eligibility on autotransplant protocols
Histologically-confirmed diagnosis of Follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia(CLL), or diffuse large B-cell lymphoma (DLBCL) a. Subjects must have disease that has relapsed or is refractory to  or more prior regimens and in need of treatment due to progressive disease
Inclusion Criteria:\n\n        To be eligible for inclusion in the primary escalation and expansion cohort  in this\n        study, patients must meet all of the following criteria:\n\n          . Age  years or older\n\n          . Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL):\n\n               . History of histologically documented CLL or SLL that meets IWCLL diagnostic\n                  criteria according to the  guidelines, and\n\n               . Indication for treatment as defined by the  IWCLL guidelines, or the need for\n                  disease reduction prior to allogeneic transplantation\n\n        Exclusion Criteria:\n\n        Patients who meet any of the following criteria are not eligible for the primary escalation\n        and expansion cohorts of this study:\n\n          . Current or past transformation of CLL/SLL to prolymphocytic leukemia (PLL),\n             non-Hodgkin lymphoma, or Hodgkin lymphoma aggressive lymphoma outlined in the\n             inclusion criteria for the optional cohort.\n\n          . Active and uncontrolled autoimmune cytopenia(s)\n\n          . Any of the following prior therapies within  days prior to cycle , day :\n\n               . Major surgery\n\n               . Corticosteroids greater than  mg / day prednisone (or equivalent), unless used\n                  by inhalation or topical route, or unless necessary for premedication before\n                  iodinated contrast dye, or for autoimmune hemolytic anemia\n\n               . Cytotoxic chemotherapy or biologic therapy, excepting BCR pathway kinase\n                  inhibitors for which no wash out is required (but must be stopped before cycle \n                  day )
Must have histologically or flow cytometry confirmed diagnosis of B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL) according to National Cancer Institute Working Group (NCI-WG)  guidelines; the malignant B cells must co-express CD with CD or CD; patients who lack CD expression on their leukemia cells should be examined for (and found NOT to have) either t(;) or cyclin D overexpression, to rule out mantle cell lymphoma; patients with CLL who have progressed on prior ibrutinib therapy will be eligible; patients with B-cell prolymphocytic leukemia and patients with Richters transformation of CLL/SLL are NOT eligible
Patients with relapsed/refractory CD+ non-Hodgkins lymphoma of the following subtypes: \r\n* Diffuse large B-cell lymphoma (DLBCL) \r\n* Mantle cell lymphoma (MCL)\r\n* Follicular lymphoma (FL)\r\n* Chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL)\r\n* Burkitts Lymphoma
Diagnosis of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) that meets IWCLL diagnostic criteria.
Histologically documented (by history of present illness [HPI] or pathology report) iNHL as defined by follicular lymphoma (FL), marginal zone lymphoma (MZL), lymphoplasmacytic lymphoma/Waldenstrom disease (LPL/WM) and small lymphocytic lymphoma (SLL) or tiNHL as defined by large B cell transformation of any of the above entities including chronic lymphocytic leukemia (CLL)
Histological confirmation of biopsy-proven non-Hodgkin lymphoma, excluding chronic lymphocytic leukemia, primary central nervous system (CNS) lymphoma and Burkitts lymphoma; Note: small lymphocytic lymphoma (SLL) is allowed
Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), or high-grade lymphomas (Burkitts lymphoma/lymphoblastic lymphoma)
Relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone B-cell lymphoma, follicular lymphoma, which have progressed within  months of achieving a partial or complete remission; patients who had remissions lasting >  months, are eligible after at least two prior therapies; patients with bulky disease should be considered for debulking chemotherapy before transplant; patients with refractory disease are eligible, unless bulky disease and an estimated tumor doubling time of less than one month
Small lymphocytic lymphoma
Patients with chemo-sensitive chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with persistent or recurrent disease after fludarabine-based regimens with < % involvement by CLL/SLL cells
Patients with a diagnosis of chronic lymphocytic leukemia (CLL) or other B-cell neoplasms including small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL) and follicular B-cell non-Hodgkin's lymphoma (FL) who have no available approved therapies.
Small lymphocytic lymphoma (SLL), or chronic lymphocytic leukemia (CLL) with progressive disease following a minimum of two lines of standard therapy
Relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone B-cell lymphoma, follicular lymphoma which have progressed within  months of achieving a partial or complete remission; patients who had remissions lasting >  months, are eligible after at least two prior therapies; patients with bulky disease should be considered for debulking chemotherapy before transplant; patients with refractory disease are eligible, unless bulky disease and an estimated tumor doubling time of less than one month
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone b-cell lymphoma or follicular lymphoma are eligible if there was disease progression/relapse within  of achieving a partial or complete remission; patients who had remissions lasting >  months, are eligible after at least two prior therapies; patients with bulky disease (nodal mass greater than  cm) should be considered for de-bulking chemotherapy before transplant
For an indolent lymphoma histology (follicular lymphoma, small lymphocytic lymphoma [SLL]/chronic lymphocytic leukemia [CLL]) or mantle cell lymphoma, the patient should not have an HLA-matched sibling, who would be an eligible donor, available
Documented CD+ chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
Small lymphocytic lymphoma with absolute lymphocyte count <xE/L at study entry
Participants with a diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
Small lymphocytic lymphoma(SLL) with absolute lymphocyte count <x*/L at study entry
Have documented chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) according to National Cancer Institute (NCI) criteria
Confirmed B-cell non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and other B-cell lymphoproliferative disorders as approved by the Medical Monitor or Study Chair
Patients with small lymphocytic lymphoma (SLL)/chronic lymphocytic leukemia (CLL) are excluded during the phase I portion of the study
Histologically confirmed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
Low-grade non-Hodgkin lymphoma (including small lymphocytic lymphoma [SLL] and chronic lymphocytic leukemia [CLL]) or plasma cell neoplasm that has progressed after at least two prior therapies (excluding single agent rituximab and single agent steroids), or in the case of lymphoma undergone histologic conversion; patients with transformed lymphomas must have stable disease or better
Patients must have the following CD+ B cell leukemia or lymphoma either with relapsed or chemotherapy-refractory disease or with evidence of residual disease following therapy; in all cases, patients disease must be confirmed at Memorial Sloan-Kettering Cancer Center (MSKCC)\r\n* Chronic lymphocytic leukemia (CLL): Patients must have a diagnosis of CLL as evidenced by flow cytometry, bone marrow histology, and/or cytogenetics\r\n* Other low grade B-cell neoplasms are eligible for study, such as small lymphocytic lymphoma (SLL), follicular lymphoma, Waldenstroms macroglobulinemia, hairy cell leukemia, marginal zone lymphomas, and mantle cell lymphomas
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone B-cell lymphoma or follicular lymphoma are eligible if there was disease progression/relapse within  of achieving a partial or complete remission; patients who had remissions lasting >  months, are eligible after at least two prior therapies; patients with bulky disease (nodal mass greater than  cm) should be considered for debulking chemotherapy before transplant
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone B-cell lymphoma, follicular lymphoma, which have progressed within  months of achieving a partial or complete remission; patients who had remissions lasting >  months, are eligible after at least two prior therapies; patients with bulky disease should be considered for debulking chemotherapy before transplant; patients with refractory disease are eligible, unless has bulky disease and an estimated tumor doubling time of less than one month
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone B-cell lymphoma or follicular lymphoma are eligible if there was disease progression/relapse within  of achieving a partial or complete remission; patients who had remissions lasting >  months, are eligible after at least two prior therapies; patients with bulky disease (nodal mass greater than  cm) should be considered for debulking chemotherapy before transplant
Patients with a history of CD+ lymphoid malignancy defined as acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), small lymphocytic lymphoma (SLL), or chronic lymphocytic leukemia (CLL) with active disease defined by presence of > % malignant blasts in bone marrow and/or peripheral blood, and/or minimal residual disease by flow cytometry or molecular analysis for fusion proteins, and/or positive imaging for extramedullary disease. Patients must have measurable disease at time of study treatment.
Histological confirmation of relapsed/refractory B-cell NHL, CD+ \r\n* NOTE: patients with small lymphocytic lymphoma (SLL) are eligible however patients with chronic lymphocytic leukemia (CLL) are not eligible\r\n* Waldenstrom macroglobulinemia patients are not eligible; aggressive lymphoma patients who are transplant eligible must have undergone a transplant\r\n* The biopsy confirming relapse can be up to  weeks prior to registration as long as there is no intervening therapy
Diagnosis of CLL without the following: Richter's transformation, prolymphocytic leukemia (PLL), small lymphocytic lymphoma (SLL)
Small lymphocytic lymphoma (SLL) or chronic lymphocytic leukemia (CLL)\r\n* Patients will be eligible in >= first complete remission (CR) with molecularly negative disease\r\n* Patients in CR with molecularly positive disease or in PR will be excluded from autologous transplant
Chronic lymphocytic leukemia/small lymphocytic lymphoma (SLL)
Subject who has histologically confirmed and documented B-cell lymphoma (eg, follicular, diffuse large B-cell, mantle cell, small lymphocytic, or Hodgkin lymphoma) and chronic lymphocytic leukemia.
Subject who has high-risk chronic lymphocytic leukemia/small lymphocytic lymphoma.
Patients must have histologically identified chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) as defined by the World Health Organization (WHO) classification of hematopoietic neoplasms
Participants with confirmed mantle cell lymphoma (MCL) or small lymphocytic lymphoma (SLL) Expansion Portion of the Study:
Participants must have confirmed CLL/small lymphocytic lymphoma (SLL) relapsed after at least one prior therapy and currently in need of treatment by IWCLL  criteria
Small lymphocytic lymphoma (SLL) with absolute lymphocyte count <  x */L at the time of diagnosis and at study entry.
Histologically confirmed B-cell non-Hodgkin lymphoma (B-NHL), Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Confirmed diagnosis of mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL)
Patients with other aggressive B-cell malignancies including, but not limited to: Burkitt lymphoma, transformed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and transformed marginal zone lymphoma that are not included above in the inclusion criteria
Documented CD+ chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
Small lymphocytic lymphoma (SLL) with absolute lymphocyte count <  x /L at the time of diagnosis and at study entry
Diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that meets protocol-defined criteria
Histologically-confirmed advanced solid tumor, chronic lymphocytic leukemia, small lymphocytic lymphoma, T-cell prolymphocytic leukemia, Non-Hodgkin Lymphoma or multiple myeloma
Patients will have a diagnosis of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or cluster of differentiation (CD) positive low-grade lymphoproliferative disorder
B-chronic lymphocytic leukemia (CLL), small lympho(plasma)cytic lymphoma (B-SLL, B-LPL)\r\n* Relapse/progression after fludarabine (fludarabine phosphate) and at least one other salvage regimen or  standard regimens\r\n* If p deletion present, one standard regimen is sufficient
Small lymphocytic lymphoma (SLL), or chronic lymphocytic leukemia (CLL) with progressive disease following standard therapy; or
Patients with lymphoma (non-Hodgkin lymphoma [NHL], chronic lymphocytic leukemia/small lymphocytic lymphoma [CLL/SLL] or Hodgkin's lymphoma) with primary refractory or relapsed disease after standard chemotherapy at high risk of relapse with conventional autografting; patients with a diagnosis of CLL (or small lymphocytic lymphoma) or diagnosis of CLL that progresses to prolymphocytic leukemia (PLL), or T-cell CLL or PLL
Small lymphocytic lymphoma (SLL) with absolute lymphocyte count <  x ^/L at the time of diagnosis
Histologically confirmed Richter's transformation (RT) from chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Clinical evidence of other indolent forms of lymphoma (e.g., marginal zone lymphoma [MZL], small lymphocytic lymphoma [SLL])
Known HIV infection and histologically confirmed B-cell non-Hodgkin lymphoma or B-cell lymphoproliferative disease as follows, as defined by the World Health Organization classification:\r\n* Active B-cell non-Hodgkin lymphoma (cluster of differentiation [CD] positive or negative), chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), or multiple myeloma that has relapsed, progressed, or been refractory to at least one regimen\r\n* Note: Patients with CLL, SLL, or mantle cell lymphoma (MCL) may only be enrolled in Stratum C
Histological confirmation of biopsy-proven B-cell non-Hodgkins lymphoma, excluding chronic lymphocytic leukemia/small lymphocytic lymphoma, primary central nervous system (CNS) lymphoma and Burkitts lymphoma
\Indolent lymphoma\ is included, and refers to small lymphocytic lymphoma/B-cell chronic lymphocytic leukemia (SLL/CLL); lymphoplasmacytic lymphoma (with or without Waldenstroms macroglobulinemia); hairy cell leukemia; follicular lymphoma (FL) of any grade; marginal zone B-cell lymphoma; or mantle cell lymphoma
Small lymphocytic lymphoma (SLL) with absolute lymphocyte count
Patients with CD-expressing B-cell NHL that is relapsed or refractory to standard therapy. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with peripheral blood leukemia/lymphoma cells and high-grade lymphomas are excluded
Patients must have histologically confirmed Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma.
Low-grade non-Hodgkins lymphoma or plasma cell neoplasm with either of the following, and with stable disease or better prior to transplantation:\r\n* Progressed during multiagent therapy, failed at least two prior therapies (excluding single agent rituximab), or there is evidence of prior transformation\r\n* Small lymphocytic lymphoma (SLL) or chronic lymphocytic leukemia (CLL) with q or p deletion or with progression <  months after a purine analog-containing regimen
CLL, Grade b follicular lymphoma or evidence that the indolent lymphoma has transformed to aggressive lymphoma. Subjects suspicious for transformation should undergo a biopsy to exclude the possibility of transformation. Subjects with a previous diagnosis of small lymphocytic leukemia (SLL) and a screening monoclonal B-lymphocyte count of ? /l are defined by  International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria to have CLL; such patients are NOT eligible for this study.
Small lymphocytic lymphoma (SLL)
Chronic lymphocytic leukemia, small lymphocytic lymphoma (SLL), or grade  follicular lymphoma
PHASE I: Histological confirmation of relapsed (recurrent after previous therapy[ies]) or refractory (no response to previous therapy[ies]) B-cell NHL; note: patients with small lymphocytic lymphoma (SLL) are eligible however patients with chronic lymphocytic leukemia (CLL) are not eligible
Small lymphocytic lymphoma (SLL) or chronic lymphocytic leukemia (CLL) with p deletion, or with progression <  months after second or greater treatment regimen; must have the following to be an acceptable candidate as well:\r\n* =< % of bone marrow cellularity involved by SLL/CLL (to lower risk of graft rejection)\r\n* No lymph nodes >=  cm in any dimension\r\n* No massive splenomegaly, defined as >  cm below the left costal margin
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone B-Cell lymphoma, follicular lymphoma, which have progressed within  months of achieving a partial or complete remission; patients who had remissions lasting >  months, are eligible after at least two prior therapies; patients with bulky disease should be considered for debulking chemotherapy before transplant; patients with refractory disease are eligible, unless has bulky disease and an estimated tumor doubling time of less than one month
Subjects with chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular, marginal zone, diffuse large B cell, Hodgkin's lymphoma, or mantle cell lymphoma must have chemosensitive disease at time of transplant.
Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular, marginal zone, diffuse large B-cell, Hodgkin lymphoma, or mantle cell lymphoma with chemosensitive disease at time of transplantation; all types of lymphoma are eligible
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone B-cell lymphoma, follicular lymphoma, which have progressed within  months of achieving a partial or complete remission; patients who had remissions lasting >  months are eligible after at least two prior therapies; patients with bulky disease should be considered for debulking chemotherapy before transplant; patients with refractory disease are eligible, unless has bulky disease and an estimated tumor doubling time of less than one month
Newly diagnosed aggressive lymphoma or CLL/small lymphocytic lymphoma (SLL) that meets disease specific criteria below:
Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma; follicular, marginal zone, diffuse large B-cell or mantle cell lymphoma with chemo-sensitive disease at time of transplant
Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular, marginal zone, diffuse large B-cell, Hodgkin's Lymphoma,or mantle cell lymphoma with chemosensitive disease at time of transplantation
No concurrent, active malignancy, other than non-metastatic skin cancer of any type, superficial bladder cancer, or early stage chronic lymphocytic leukemia (well-differentiated small cell lymphocytic lymphoma) or < stage IV follicular lymphoma; if a prior malignancy is in remission for >=  years then the patient is eligible
